Literature DB >> 28506438

Prion-like Spreading in Tauopathies.

Jacob I Ayers1, Benoit I Giasson1, David R Borchelt2.   

Abstract

Tau is a microtubule-associated protein that functions in regulating cytoskeleton dynamics, especially in neurons. Misfolded and aggregated forms of tau produce pathological structures in a number of neurodegenerative diseases, including Alzheimer's disease (AD) and tauopathy dementias. These disorders can present with a sporadic etiology, such as in AD, or a familial etiology, such as in some cases of frontotemporal dementia with parkinsonism. Notably, the pathological features of tau pathology in these diseases can be very distinct. For example, the tau pathology in corticobasal degeneration is distinct from that of an AD patient. A wealth of evidence has emerged within the last decade to suggest that the misfolded tau in tauopathies possesses prion-like features and that such features may explain the diverse characteristics of tauopathies. The prion-like concept for tauopathies arose initially from the observation that the progressive accumulation of tau pathology as the symptoms of AD progress seemed to follow anatomically linked pathways. Subsequent studies in cell and animal models revealed that misfolded tau can propagate from cell to cell and from region to region in the brain through direct neuroanatomical connections. Studies in these cell and mouse models have demonstrated that experimentally propagated forms of misfolded tau can exist as conformationally distinct "strains" with unique biochemical, morphological, and neuropathological characteristics. This review discusses the clinical, pathological, and genetic diversity of tauopathies and the discoveries underlying the emerging view that the unique features of clinically distinct tauopathies may be a reflection of the strain of misfolded tau that propagates in each disease.
Copyright © 2017 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer’s disease; Animal models; Prion; Strains; Tau; Transmission

Mesh:

Substances:

Year:  2017        PMID: 28506438      PMCID: PMC5640465          DOI: 10.1016/j.biopsych.2017.04.003

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  153 in total

1.  Straight and paired helical filaments in Alzheimer disease have a common structural unit.

Authors:  R A Crowther
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-15       Impact factor: 11.205

Review 2.  Cellular factors modulating the mechanism of tau protein aggregation.

Authors:  Sarah N Fontaine; Jonathan J Sabbagh; Jeremy Baker; Carlos R Martinez-Licha; April Darling; Chad A Dickey
Journal:  Cell Mol Life Sci       Date:  2015-02-11       Impact factor: 9.261

3.  Ubiquitin is conjugated with amino-terminally processed tau in paired helical filaments.

Authors:  M Morishima-Kawashima; M Hasegawa; K Takio; M Suzuki; K Titani; Y Ihara
Journal:  Neuron       Date:  1993-06       Impact factor: 17.173

4.  Transgene expression in the Nop-tTA driver line is not inherently restricted to the entorhinal cortex.

Authors:  Michael J Yetman; Sveinung Lillehaug; Jan G Bjaalie; Trygve B Leergaard; Joanna L Jankowsky
Journal:  Brain Struct Funct       Date:  2015-04-14       Impact factor: 3.270

5.  New phosphorylation sites identified in hyperphosphorylated tau (paired helical filament-tau) from Alzheimer's disease brain using nanoelectrospray mass spectrometry.

Authors:  D P Hanger; J C Betts; T L Loviny; W P Blackstock; B H Anderton
Journal:  J Neurochem       Date:  1998-12       Impact factor: 5.372

6.  Fibrillogenic nuclei composed of P301L mutant tau induce elongation of P301L tau but not wild-type tau.

Authors:  Hirofumi Aoyagi; Masato Hasegawa; Akira Tamaoka
Journal:  J Biol Chem       Date:  2007-05-25       Impact factor: 5.157

7.  Analysis of microtubule-associated protein tau glycation in paired helical filaments.

Authors:  M D Ledesma; P Bonay; C Colaço; J Avila
Journal:  J Biol Chem       Date:  1994-08-26       Impact factor: 5.157

8.  Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease.

Authors:  M Goedert; M G Spillantini; R Jakes; D Rutherford; R A Crowther
Journal:  Neuron       Date:  1989-10       Impact factor: 17.173

9.  Distinct tau prion strains propagate in cells and mice and define different tauopathies.

Authors:  David W Sanders; Sarah K Kaufman; Sarah L DeVos; Apurwa M Sharma; Hilda Mirbaha; Aimin Li; Scarlett J Barker; Alex C Foley; Julian R Thorpe; Louise C Serpell; Timothy M Miller; Lea T Grinberg; William W Seeley; Marc I Diamond
Journal:  Neuron       Date:  2014-05-22       Impact factor: 17.173

10.  Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry.

Authors:  Heiko Braak; Irina Alafuzoff; Thomas Arzberger; Hans Kretzschmar; Kelly Del Tredici
Journal:  Acta Neuropathol       Date:  2006-08-12       Impact factor: 17.088

View more
  31 in total

1.  Discovery of 4-Piperazine Isoquinoline Derivatives as Potent and Brain-Permeable Tau Prion Inhibitors with CDK8 Activity.

Authors:  Jean-Marc M Grandjean; Alexander Y Jiu; John W West; Atsushi Aoyagi; Daniel G Droege; Manuel Elepano; Makoto Hirasawa; Masakazu Hirouchi; Ryo Murakami; Joanne Lee; Koji Sasaki; Shimpei Hirano; Takao Ohyama; Benjamin C Tang; Roy J Vaz; Masahiro Inoue; Steven H Olson; Stanley B Prusiner; Jay Conrad; Nick A Paras
Journal:  ACS Med Chem Lett       Date:  2020-01-30       Impact factor: 4.345

2.  Aβ and tau prion-like activities decline with longevity in the Alzheimer's disease human brain.

Authors:  Atsushi Aoyagi; Carlo Condello; Jan Stöhr; Weizhou Yue; Brianna M Rivera; Joanne C Lee; Amanda L Woerman; Glenda Halliday; Sjoerd van Duinen; Martin Ingelsson; Lars Lannfelt; Caroline Graff; Thomas D Bird; C Dirk Keene; William W Seeley; William F DeGrado; Stanley B Prusiner
Journal:  Sci Transl Med       Date:  2019-05-01       Impact factor: 17.956

3.  SIRT1: A Novel Way to Target Tau?

Authors:  Hunter S Futch; Cara L Croft
Journal:  J Neurosci       Date:  2018-09-05       Impact factor: 6.167

4.  Phosphorylation of serine 305 in tau inhibits aggregation.

Authors:  Kevin H Strang; Zachary A Sorrentino; Cara J Riffe; Kimberly-Marie M Gorion; Niran Vijayaraghavan; Todd E Golde; Benoit I Giasson
Journal:  Neurosci Lett       Date:  2018-11-10       Impact factor: 3.046

5.  Distinct differences in prion-like seeding and aggregation between Tau protein variants provide mechanistic insights into tauopathies.

Authors:  Kevin H Strang; Cara L Croft; Zachary A Sorrentino; Paramita Chakrabarty; Todd E Golde; Benoit I Giasson
Journal:  J Biol Chem       Date:  2017-12-19       Impact factor: 5.157

6.  Corticobasal degeneration: key emerging issues.

Authors:  F Ali; K A Josephs
Journal:  J Neurol       Date:  2017-10-23       Impact factor: 4.849

Review 7.  Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2019-06-18       Impact factor: 3.575

8.  Emerging Mechanisms in Alzheimer's Disease and Their Therapeutic Implications.

Authors:  Stephen M Strittmatter
Journal:  Biol Psychiatry       Date:  2018-02-15       Impact factor: 13.382

9.  Structural disorder in four-repeat Tau fibrils reveals a new mechanism for barriers to cross-seeding of Tau isoforms.

Authors:  Hilary A Weismiller; Rachel Murphy; Guanghong Wei; Buyong Ma; Ruth Nussinov; Martin Margittai
Journal:  J Biol Chem       Date:  2018-09-21       Impact factor: 5.157

10.  Impaired tau-microtubule interactions are prevalent among pathogenic tau variants arising from missense mutations.

Authors:  Yuxing Xia; Zachary A Sorrentino; Justin D Kim; Kevin H Strang; Cara J Riffe; Benoit I Giasson
Journal:  J Biol Chem       Date:  2019-10-24       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.